Use of Baricitenib to Maintain of Remission

Baricitinib a selective Janus kinase (JAK) inhibitors 1&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.

Inclusion Criteria:Clinical diagnosis of Lupus nephritis DiseaseMust be able to swallow tabletslupus nephritis in remissionExclusion Criteria:antiphospholipid syndrome diseasethrombosis historysever anemia, leukopenia or thrombocytopeniaimpaired liver and renal function